CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.
间充质干细胞(MSCs)被认为是癌症治疗的有前景的来源,并可作为癌症基因治疗的载体。
间充质干细胞(MSCs)被认为是癌症治疗的有前景的来源,并且可以作为癌症基因治疗中的载体。MSC来源的外泌体是MSCs治疗功能的中心介质,被称为基于MSC的细胞治疗的新型无细胞替代方案。与MSCs移植治疗相比,MSC来源的外泌体显示出优势,包括更高的安全性以及更稳定的储存、运输和给药便利性。未修饰的MSC来源的外泌体可以促进或抑制肿瘤,而修饰的MSC来源的外泌体通过递送几种治疗分子,包括化疗药物、miRNAs、抗miRNAs、特异性siRNAs和自杀基因mRNAs,参与抑制癌症的发展和进展。在大多数恶性肿瘤中,miRNAs的失调不仅作为癌症进展的结果发生,而且由于其作为癌基因(oncomiRs)或肿瘤抑制因子(TS-miRNAs)的作用,直接参与肿瘤的发生和发展。MiRNA恢复通常通过使用合成的miRNA模拟物和病毒载体过表达TS-miRNAs,或甚至通过抗miRNAs下调oncomiRs来实现。与其他治疗分子类似,miRNAs恢复在癌症治疗中的疗效取决于递送系统的有效性。在本综述中,我们首先概述了MSCs在癌症治疗中的特性和潜力,以及MSC来源的外泌体在癌症治疗中的应用。最后,我们特别关注利用MSC来源的外泌体用于癌症治疗中miRNA递送的目的。
Mesenchymal stem cells (MSCs) are known as promising sources for cancer therapy and can be utilized as vehicles in cancer gene therapy. MSC-derived exosomes are central mediators in the therapeutic functions of MSCs, known as the novel cell-free alternatives to MSC-based cell therapy. MSC-derived exosomes show advantages including higher safety as well as more stability and convenience for storage, transport and administration compared to MSCs transplant therapy. Unmodified MSC-derived exosomes can promote or inhibit tumors while modified MSC-derived exosomes are involved in the suppression of cancer development and progression via the delivery of several therapeutics molecules including chemotherapeutic drugs, miRNAs, anti-miRNAs, specific siRNAs, and suicide gene mRNAs. In most malignancies, dysregulation of miRNAs not only occurs as a consequence of cancer progression but also is directly involved during tumor initiation and development due to their roles as oncogenes (oncomiRs) or tumor suppressors (TS-miRNAs). MiRNA restoration is usually achieved by overexpression of TS-miRNAs using synthetic miRNA mimics and viral vectors or even downregulation of oncomiRs using anti-miRNAs. Similar to other therapeutic molecules, the efficacy of miRNAs restoration in cancer therapy depends on the effectiveness of the delivery system. In the present review, we first provided an overview of the properties and potentials of MSCs in cancer therapy as well as the application of MSC-derived exosomes in cancer therapy. Finally, we specifically focused on harnessing the MSC-derived exosomes for the aim of miRNA delivery in cancer therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。